Literature DB >> 20136168

Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations.

Cinzia Maraldi1, Fabrizia Lattanzio, Graziano Onder, Massimo Gallerani, Silvia Bustacchini, Giuseppe De Tommaso, Stefano Volpato.   

Abstract

In western countries approximately a quarter of the population is 65 years and older. People in this age group often have several coexisting medical problems and take multiple drugs, and older people receive the greatest proportion of dispensed prescriptions. The prevalence of cardiovascular diseases, the leading cause of death and a major cause of physical and cognitive disability, increases steeply with increasing age. Drugs for the prevention and treatment of cardiovascular conditions account for a large proportion of medication prescription in older persons. Despite a number of published guidelines and expert recommendations supporting a standardized use of many cardiovascular agents, there is growing evidence of a tremendous variability in cardiovascular drug prescriptions according to demographics, health characteristics, and setting of care. In particular, evidence shows an inverse relationship between treatment propensity and age. To date, there is little evidence of benefit of most pharmacotherapy in frail, older subjects or elderly individuals with multiple comorbidities and polypharmacotherapy. However, effective treatment should not be denied solely on the basis of age. A major challenge in geriatric practice is to ensure safe and effective pharmacological treatments, avoiding the risk of polypharmacy and inappropriate drug prescription.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20136168     DOI: 10.2165/11534650-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  102 in total

1.  Characteristics of patients with uncontrolled hypertension in the United States.

Authors:  D J Hyman; V N Pavlik
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

2.  Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; Gregory Y H Lip; S Bertil Olsson; Martin H Prins; Fred H Nieman; José López-Sendón; Panos E Vardas; Etienne Aliot; Massimo Santini; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2006-05-26       Impact factor: 29.983

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

4.  Audit of secondary prophylaxis after myocardial infarction.

Authors:  D L Whitford; A J Southern
Journal:  BMJ       Date:  1994-11-12

5.  Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy.

Authors:  E Ambrosioni; G Leonetti; A C Pessina; A Rappelli; B Trimarco; A Zanchetti
Journal:  J Hypertens       Date:  2000-11       Impact factor: 4.844

6.  Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation.

Authors:  R Thomson; D Parkin; M Eccles; M Sudlow; A Robinson
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

7.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

9.  Low prevalence of lipid lowering drug use in older men with established coronary heart disease.

Authors:  P H Whincup; J R Emberson; L Lennon; M Walker; O Papacosta; A Thomson
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  3 in total

Review 1.  Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review.

Authors:  Salmaan Kanji; Dugald Seely; Fatemeh Yazdi; Jennifer Tetzlaff; Kavita Singh; Alexander Tsertsvadze; Andrea C Tricco; Margaret E Sears; Teik C Ooi; Michele A Turek; Becky Skidmore; Mohammed T Ansari
Journal:  Syst Rev       Date:  2012-05-31

2.  Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population.

Authors:  Caroline Laborde; Jérémy Barben; Anca-Maria Mihai; Valentine Nuss; Jérémie Vovelle; Philippe d'Athis; Pierre Jouanny; Alain Putot; Patrick Manckoundia
Journal:  Int J Environ Res Public Health       Date:  2020-06-24       Impact factor: 3.390

3.  Number of medications is associated with outcomes in the elderly patient with metabolic syndrome.

Authors:  Akshar Y Patel; Pratik Shah; Joseph H Flaherty
Journal:  J Geriatr Cardiol       Date:  2012-09       Impact factor: 3.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.